US 12,251,382 B2
Substituted amino-pyrimidine compound for use in a method for treatment and prevention of multiple sclerosis
Martin Dyroff, Wayland, MA (US); David Mitchell, Broomfield, CO (US); and Orestis Papasouliotis, Geneva (CH)
Assigned to Merck Patent GmbH, Darmstadt (DE)
Appl. No. 17/261,407
Filed by Merck Patent GmbH, Darmstadt (DE)
PCT Filed Jul. 19, 2019, PCT No. PCT/IB2019/056198
§ 371(c)(1), (2) Date Jan. 19, 2021,
PCT Pub. No. WO2020/016850, PCT Pub. Date Jan. 23, 2020.
Claims priority of provisional application 62/839,273, filed on Apr. 26, 2019.
Claims priority of provisional application 62/730,184, filed on Sep. 12, 2018.
Claims priority of provisional application 62/700,977, filed on Jul. 20, 2018.
Prior Publication US 2021/0260060 A1, Aug. 26, 2021
Int. Cl. A61K 31/506 (2006.01); A61K 9/00 (2006.01); A61P 25/28 (2006.01)
CPC A61K 31/506 (2013.01) [A61K 9/0053 (2013.01); A61P 25/28 (2018.01)] 32 Claims
 
1. A method for treating multiple sclerosis, the method comprising:
orally administering to a patient in need thereof, a compound of Formula I at a daily amount ranging from about 85 mg to about 95 mg, or a pharmaceutically acceptable salt thereof, wherein Formula I is represented by:

OG Complex Work Unit Chemistry
wherein the multiple sclerosis is relapsing multiple sclerosis, relapsing-remitting multiple sclerosis, secondary-progressive multiple sclerosis, or progressive-relapsing multiple sclerosis,
wherein the compound of Formula I or the pharmaceutically acceptable salt thereof is administered twice per day, and
wherein
(i) the patient has consumed food within 1 hour prior to receiving said compound;
(ii) the administering is performed at a time the patient consumes a meal; or
(iii) the patient consumes a meal within 1 hour of receiving said compound.